map1lc3b lc3b  (Novus Biologicals)

Journal: Neurosurgical Review

Article Title: Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential

doi: 10.1007/s10143-025-04050-7

Figure Lengend Snippet: (A) Diffuse/fibrillary strong PD-L1 expression in glioblastoma (IHC, x400). (B) Diffuse/fibrillary PD-L1 moderate expression in glioblastoma (IHC, x200). (C) Diffuse/fibrillary and cytoplasmic weak PD-L1 expression in glioblastoma (IHC, x400). (D) High LC3B cytoplasmic expression in glioblastoma (IHC, x400). (E) Low LC3B expression in glioblastoma (IHC, x200)

Article Snippet: The sections placed in an endogenous peroxide block for 15 min and For purpose of antigen retrieval for both PDL-1 & LC3B, sections were treated in microwave of (600 W) by immersion of the slides in citrate puffer solution (PH 7) for 20 min subsequently applied PD-L1 (mouse monoclonal antibodies, CUSABIO, Houston, USA, clone no.14D8C2, product code: CSB-MA878942A1m, 1: 200 [ ]) and LC3B (mouse monoclonal antibody, CUSABIO, Houston, USA, Clone No. 18F2, Product Code CSB-MA171423, a dilution of 1: 100 for 60 min, and then immunocomplexes were visualized with diaminobenzidine for 10 min and covered by a coverslip.

Techniques: Expressing

Journal: Neurosurgical Review

Article Title: Dual biomarker role of PD-L1 and LC3B in glioblastoma: prognostic and therapeutic potential

doi: 10.1007/s10143-025-04050-7

Figure Lengend Snippet: OS according to expression of each PD-L1& LC3B and PFS according to LC3B; ( A ) OS in patients with high PD-L1 expression= 8.07 ± 0.62(Mean±SE) with 95% C.I (6.85-9.281), moderate expression OS= 9.65 ± 1.00 with 95% C.I (7.68-11.62) and weak PD-L1 expression OS=23.14 ±1.26with 95%C.I (20.67-25.60). ( B ) OS in cases with high LC3B expression=9.88 ± 1.19 (Mean±SE) with 95%C.I (7.55-12.21), and in those with low expression =20.77 ± 1.42 with 95%C.I (17.99-23.56). ( C ) PFS in cases with High LC3B expression = 2.93 ± 0.33(Mean±S.E )with 95%C.I=2.27-3.58. PFS in cases with Low expression =8.47 ± 0.36 with 95%C.I =7.75-9.18

Article Snippet: The sections placed in an endogenous peroxide block for 15 min and For purpose of antigen retrieval for both PDL-1 & LC3B, sections were treated in microwave of (600 W) by immersion of the slides in citrate puffer solution (PH 7) for 20 min subsequently applied PD-L1 (mouse monoclonal antibodies, CUSABIO, Houston, USA, clone no.14D8C2, product code: CSB-MA878942A1m, 1: 200 [ ]) and LC3B (mouse monoclonal antibody, CUSABIO, Houston, USA, Clone No. 18F2, Product Code CSB-MA171423, a dilution of 1: 100 for 60 min, and then immunocomplexes were visualized with diaminobenzidine for 10 min and covered by a coverslip.

Techniques: Expressing

Journal: Microorganisms

Article Title: Legionella pneumophila -Induced NETs Do Not Bear LL-37 Peptides

doi: 10.3390/microorganisms13102298

Figure Lengend Snippet: L. pneumophila -induced autophagy in different types of cells, macrophages and neutrophils. Fluorescence confocal microscopy images showing autophagy staining (blue: DAPI; red: LC3b). A representative example of 5 independent experiments is shown. ( A ) Study of autophagy on THP1 macrophages: (1) Untreated cells; (2) Cells stimulated with clarithromycin; (3) Cells stimulated with clarithromycin with inhibitors; (4) Cells stimulated with NETs from LD patients; (5) Cells stimulated with NETs from LD patients with inhibitors; (6) Cells stimulated with in vitro isolated NETs, after stimulation of control neutrophils with L. pneumophila ; (7) Cells stimulated with in vitro isolated NETs, after stimulation of control neutrophils with L. pneumophila with inhibitors. ( B ) Study of autophagy on ex vivo or in vitro neutrophils: (1) Untreated HI neutrophils; (2) HI neutrophils with clarithromycin; (3) HI neutrophils with clarithromycin with inhibitors; (4) Neutrophils from LD patients; (5) In vitro isolated HI neutrophils stimulated with L. pneumophila .

Article Snippet: To study autophagy induction, samples were stained with anti-LC3b polyclonal antibody (1:100 dilution, OriGene Technologies GmbH, Herford, Germany), followed by a polyclonal anti-mouse IgG AlexaFluor488 antibody (Invitrogen, Waltham, MA, USA) as a secondary antibody.

Techniques: Fluorescence, Confocal Microscopy, Staining, In Vitro, Isolation, Control, Ex Vivo